US › Healthcare

Jade Biosciences, Inc. (JBIO)

US · Healthcare · Biotechnology

$21.35+11.49%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-40.4M
Profit YoY
-1503.2%
EPS
$-0.57
EPS estimate
$-0.48

EPS came in at -0.57 against a street estimate of -0.48 — a miss of 18.7%.

Key statistics

Market cap
$1.20B
Forward P/E
0.0
P/B
4.06
Book value
$6.01
EPS (TTM)
$-2.63
52-week high
$28.00
52-week low
$6.67
50-day MA
$19.87
200-day MA
$16.52

Analyst view

Analysts rate Jade Biosciences, Inc. a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $48.50.

Shareholding

Insiders
0.83%
Institutions
97.27%

Largest institutional holders

FundStake
FMR Inc11.64%
Fairmount Funds Management LLC7.48%
RA Capital Management, LLC6.03%
Bellevue Group AG5.75%
VR Adviser, LLC5.29%
HHG PLC5.10%
Avidity Partners Management LP4.60%
BlackRock Inc3.80%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Jade Biosciences, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.